Marvel Biotechnology Chief Science Officer Mark Williams joined Steve Darling from Proactive to learn more about the company that utilizes a drug redevelopment approach to drug development. Williams explains that what means and how they go about it. Williams also chatted about their recent announcement that the company has identified a series of compounds inspired by known psychedelic molecules, that appear to be active as anti-depressants in pre-clinical testing.
Marvel Biotechnology looking to address conditions like depression using repurposed molecules
